Avid Bioservices Inc (CDMO)

[cjgaddy]

Per IR, the Liver IST Interim Data Update will occur in MARCH (NOT MAY, EBS), as promised In the 12-10-13 10K press release (Q1'14). It will occur in this March 13th presentation by UTSW's Dr. Adam Yopp...
- - - - - - -
Mar13: 2014 Society of Surgical Oncology Cancer Symposium (2014 SSO), Phoenix http://www.sso2014.org
• Adam Yopp (MD, Assist.Prof.Surgery, UTSW/Dallas): “Combination of Bavituximab and Sorafenib Inhibits HCC (Liver Cancer) Growth: Results of Preclinical Data and a Phase I Study”
=> http://ir.peregrineinc.com/events.cfm (shows Dr.Yopp's abstract)
= = = = = = = =
12-10-13 Qtly. Conf. Call (King/Shan/Garnick/Hutchins/Worsley/Lytle) Transcript http://tinyurl.com/mw777mk
PR: "A Phase I/II IST evaluating bavituximab, in combination with sorafenib in up to 48 patients with advanced hepatocellular carcinoma (Liver Cancer). Interim data has been accepted for oral presentation at an upcoming scientific conference in the first quarter of 2014."
...CC/CEO S.King: “We believe that Peregrine is uniquely positioned among the companies developing immunotherapies… and that because of our current valuation, we represent a unique investment opportunity.”
.
.
.
H. 1st Investigator-Sponsored (IST) Ph.I/II Trial (Bavi+Sorafenib vs. Liver Cancer/HCC, open-label)
...Note: Sorafenib = Onyx/Bayer's Nexavar - see http://www.nexavar.com
Protocol: http://clinicaltrials.gov/ct2/show/NCT01264705 UTSW: http://tinyurl.com/mwdc2ql (5 sites: 3/UTSW, Parkland-Hosp, Dallas/VA)
...4-4-12 AACR'12: Dr. Adam Yopp, "promising safety profile to-date" http://tinyurl.com/7yrwqm7 (see #5591)
...Feb'12-Mar'13 ~8 times: CEO Steve King hints of future ex-US partner-driven Bavi+Sorafenib/LIVER trial in Asia: http://tinyurl.com/la5t9cq
......Articles & Data describe Liver Cancer challenges in Asian populations: http://tinyurl.com/7z7o8j9 & http://tinyurl.com/7z99cy4
...12-1-10: PPHM's 1st IST (Liver Cancer) initiated at UTSW, ~56 patients - http://tinyurl.com/3xd3e6c
…Per S.King, 5-18-10/R&R, "We've had a lot of interest in running clinical trials with the compound from investigators who have either had prior experience with the drug or would like to study the drug in various settings. Potential IST indications include all the major solid tumor types. Of particular interest is Liver Cancer, in which we have a natural tie-in with our HCV program, Ovarian Cancer and Pancreatic Cancer, also very nicely supported by the prior data."